Status and phase
Conditions
Treatments
About
A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine.
Full description
There will be 2 study groups and an anticipated enrolment of 10,300 health professionals and adults with high potential for exposure to SARS-CoV-2, aged ≥18 years.
All subjects will undergo follow-up for a total of 1 year post last vaccination. Additional visits or procedures may be performed at the discretion of the investigators, e.g., further medical history and physical examination, or additional blood tests and other investigations if clinically relevant
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Re-vaccination exclusion criteria (two-dose groups only)
Primary purpose
Allocation
Interventional model
Masking
10,300 participants in 4 patient groups
Loading...
Central trial contact
Volunteer Recruitment Coordinator
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal